Fulcrum Therapeutics Reports Positive 12-Week Phase 1b PIONEER Trial Results for Pociredir in Sickle Cell Disease

Reuters02-24

<a href="https://laohu8.com/S/FULC">Fulcrum Therapeutics</a> Reports Positive 12-Week Phase 1b PIONEER Trial Results for Pociredir in Sickle Cell Disease

Fulcrum Therapeutics Inc. reported positive 12-week results from the 20 mg dose cohort (n=12) of its Phase 1b PIONEER open-label dose-escalation trial evaluating pociredir, an oral once-daily fetal hemoglobin (HbF) inducer, in adults with severe sickle cell disease. Mean absolute HbF increased from 7.1% at baseline to 19.3% at Week 12, with 7 of 12 patients reaching HbF levels of at least 20%; mean hemoglobin increased from 7.3 g/dL to 8.4 g/dL, and 7 of 12 patients reported zero vaso-occlusive crises during the treatment period. The company said additional data from the 20 mg cohort, including results through the 4-week follow-up period, will be presented at a future medical conference, and it plans to initiate a potential registration-enabling trial in the second half of 2026, pending regulatory feedback.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240700PRIMZONEFULLFEED9659582) on February 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613152287?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613152287","market":"nz","top_or_hot":-1,"title":"Fulcrum Therapeutics Reports Positive 12-Week Phase 1b PIONEER Trial Results for Pociredir in Sickle Cell Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> Reports Positive 12-Week Phase 1b PIONEER Trial Results for Pociredir in Sickle Cell Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported positive 12-week results from the 20 mg dose cohort (n=12) of its Phase 1b PIONEER open-label dose-escalation trial evaluating pociredir, an oral once-daily fetal hemoglobin (HbF) inducer, in adults with severe sickle cell disease. Mean absolute HbF increased from 7.1% at baseline to 19.3% at Week 12, with 7 of 12 patients reaching HbF levels of at least 20%; mean hemoglobin increased from 7.3 g/dL to 8.4 g/dL, and 7 of 12 patients reported zero vaso-occlusive crises during the treatment period. The company said additional data from the 20 mg cohort, including results through the 4-week follow-up period, will be presented at a future medical conference, and it plans to initiate a potential registration-enabling trial in the second half of 2026, pending regulatory feedback.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240700PRIMZONEFULLFEED9659582) on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulcrum Therapeutics Reports Positive 12-Week Phase 1b PIONEER Trial Results for Pociredir in Sickle Cell Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulcrum Therapeutics Reports Positive 12-Week Phase 1b PIONEER Trial Results for Pociredir in Sickle Cell Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> Reports Positive 12-Week Phase 1b PIONEER Trial Results for Pociredir in Sickle Cell Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported positive 12-week results from the 20 mg dose cohort (n=12) of its Phase 1b PIONEER open-label dose-escalation trial evaluating pociredir, an oral once-daily fetal hemoglobin (HbF) inducer, in adults with severe sickle cell disease. Mean absolute HbF increased from 7.1% at baseline to 19.3% at Week 12, with 7 of 12 patients reaching HbF levels of at least 20%; mean hemoglobin increased from 7.3 g/dL to 8.4 g/dL, and 7 of 12 patients reported zero vaso-occlusive crises during the treatment period. The company said additional data from the 20 mg cohort, including results through the 4-week follow-up period, will be presented at a future medical conference, and it plans to initiate a potential registration-enabling trial in the second half of 2026, pending regulatory feedback.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240700PRIMZONEFULLFEED9659582) on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FULC","symbol_name":"Fulcrum Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL3BM132:1","article_id":"2613152287","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613152287","pubTimestamp":1771934636,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fulcrum Therapeutics Inc. reported positive 12-week results from the 20 mg dose cohort  of its Phase 1b PIONEER open-label dose-escalation trial evaluating pociredir, an oral once-daily fetal hemoglobin  inducer, in adults with severe sickle cell disease. Mean absolute HbF increased from 7.1% at baseline to 19.3% at Week 12, with 7 of 12 patients reaching HbF levels of at least 20%; mean hemoglobin increased from 7.3 g/dL to 8.4 g/dL, and 7 of 12 patients reported zero vaso-occlusive crises during the treatment period. The company said additional data from the 20 mg cohort, including results through the 4-week follow-up period, will be presented at a future medical conference, and it plans to initiate a potential registration-enabling trial in the second half of 2026, pending regulatory feedback.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FULC":"Fulcrum Therapeutics","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4007":"制药","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD"},"translate_title":"Fulcrum Therapeutics报告Pociredir治疗镰状细胞病的12周1b期先锋试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"FULC":0.9},"content_text":"Fulcrum Therapeutics Reports Positive 12-Week Phase 1b PIONEER Trial Results for Pociredir in Sickle Cell Disease\n    \n\n        Fulcrum Therapeutics Inc. reported positive 12-week results from the 20 mg dose cohort (n=12) of its Phase 1b PIONEER open-label dose-escalation trial evaluating pociredir, an oral once-daily fetal hemoglobin (HbF) inducer, in adults with severe sickle cell disease. Mean absolute HbF increased from 7.1% at baseline to 19.3% at Week 12, with 7 of 12 patients reaching HbF levels of at least 20%; mean hemoglobin increased from 7.3 g/dL to 8.4 g/dL, and 7 of 12 patients reported zero vaso-occlusive crises during the treatment period. The company said additional data from the 20 mg cohort, including results through the 4-week follow-up period, will be presented at a future medical conference, and it plans to initiate a potential registration-enabling trial in the second half of 2026, pending regulatory feedback.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240700PRIMZONEFULLFEED9659582) on February 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613152287","isCrawlerRequest":true}